Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints
Daniele Fanale,Lidia Rita Corsini,Marco Bono,Ugo Randazzo,Nadia Barraco,Chiara Brando,Daniela Cancelliere,Silvia Contino,Ambra Giurintano,Luigi Magrin,Erika Pedone,Alessandro Perez,Paola Piraino,Alessia Pivetti,Emilia Di Giovanni,Tancredi Didier Bazan Russo,Ornella Prestifilippo,Vincenzo Gennusa,Gianni Pantuso,Antonio Russo,Viviana Bazan
DOI: https://doi.org/10.1016/j.critrevonc.2023.104220
Abstract:Specific tumor-derived extracellular vesicles, called exosomes, are considered as potential key players in cross-talk between immune system and tumor microenvironment in several solid tumors. Different studies highlighted the clinical relevance of exosomes in ovarian cancer (OC) for their role in early diagnosis, prognosis, chemoresistance, targeted therapy. The exosomes are nanosize vesicles carrying lipids, proteins, and nucleic acids. In particular, exosomes shuttle a wide spectrum of microRNAs (miRNAs) able to induce phenotypic reprogramming of target cells, contributing to tumor progression. In this review, we will discuss the promising role of miRNAs shuttled by exosomes, called exosomal miRNAs (exo-miRNAs), as potential biomarkers for early detection, tumour progression and metastasis, prognosis, and response to therapy in OC women, in order to search for new potential biological fingerprints able to better characterize the evolution of this malignancy and provide a clinically relevant non-invasive approach useful for adopting, in future, personalized therapeutic strategies.